logo
America is still grappling with uncomfortable pandemic truths

America is still grappling with uncomfortable pandemic truths

Yahoo11-03-2025

As we commemorate the fifth anniversary of theWorld Health Organization declaring the novel coronavirus a pandemic, this is the first of a six-part MSNBC Daily series that reflects on the million American lives lost, the political polarization and the declining trust in public health measures that followed the virus' spread and assesses the country's preparedness for the next pandemic.
An oxygen concentrator being used by Lorena Martínez (not her real name) hums like a funeral dirge in her cramped Washington, D.C., apartment, its plastic tubing snaking across the carpet that her 13-year-old daughter vacuums between homework assignments and administering her mother's insulin injections. At 37, the former bakery manager survives as a living Venn diagram of America's pandemic failures. She was infected with Sars-Cov-2 (the Covid virus) in the summer of 2020 and had a complex hospitalization resulting in a kidney transplant and an inexplicable lung condition that has left her dependent on oxygen.
Her story crystallizes the pandemic's cruel duality: Even as one part of America was questioning the efficacy of masks and social distancing, another part was fighting for breath in overwhelmed hospitals where doctors tried immunosuppressants, ventilation techniques, antivirals, antibiotics and anything else in the proverbial medical kitchen sink.
The machines that kept Lorena alive testify to medicine's triumphs; the child shouldering this burden for an overlooked community exposes its bankruptcies. Five years later, we remain two nations: one that feels justified in minimizing Covid and rejecting any mitigation strategies and the other trapped in the long memory of infections, isolation and death.
The evocative image of Covid that former President Joe Biden often cited, a family dinner table with an empty chair, is replicated in countless homes across the nation. Even so, a narrative of resilience and recovery often dominates the official discourse.
The Covid-19 pandemic reveals itself not as a singular event but as a multifaceted crisis that exposed deep-seated fault lines in American society. The numbers tell a chilling tale: over 111.8 million confirmed cases and 1.2 million lives lost as of February 2025. Yet, these statistics, as vast as they are, fail to capture the pandemic's true scope: the silent suffering, the economic devastation and the erosion of social and scientific trust.
From the outset, the pandemic cleaved the nation into two distinct camps. On one side stood those who embraced public health measures, sometimes at great personal and economic cost. This America witnessed firsthand the horrors of overwhelmed hospitals and clinics, where health care workers battled exhaustion and death daily or at least acknowledged and accepted as true reports of what was happening. The virus quickly surged past influenza, strokes, suicides and car crashes to become the third-leading cause of death in 2020 and 2021, behind only heart disease and cancer. This America, driven by a sense of collective responsibility, lined up for vaccines, wore masks religiously and curtailed social gatherings.
On the other side, beliefs that reports about the virus were false or exaggerated and concerns over personal freedom and economic hardship fueled resistance to lockdowns, mask mandates and vaccination requirements. This America viewed public health restrictions as an infringement on individual liberties, questioning the severity of the virus and the motives behind government interventions. This group of Americans, taking their cues from social media and partisan news outlets, contributed to a climate of mistrust and division.
The economic consequences of these divergent approaches have been profound. The U.S. gross domestic product contracted by 3.5% in 2020, a decrease not seen since the end of World War II. The pandemic's economic toll as of January 2023 was $4 trillion in government expenditures alone.
The government's response to the crisis was unprecedented in scale. Operation Warp Speed assembled the best scientific minds to speedily and safely develop vaccines. The CARES Act, with its Economic Impact Payments, sought to provide a lifeline to struggling Americans. The Federal Reserve slashed interest rates and implemented liquidity facilities to stabilize financial markets. These measures came at a cost, with the national debt ballooning to levels unseen in peacetime and businesses large and small suffering from stay-at-home orders and distancing requirements. Perhaps the worst have been the effects on the children who missed graduations or attended most of their classes via computer screen and the adults whose deaths were marked only by virtual forms of grief.
The most uncomfortable pandemic truths lie not in what we got wrong, but in what we refused to see in the evolution of a novel virus. Early missteps — from dismissing aerosol transmission risks to underestimating asymptomatic spread — weren't mere scientific growing pains; they were systemic failures of imagination that proved deadly for vulnerable populations. Our policy responses, though unprecedented in scale, became Rorschach tests for America's structural inequities. While white-collar workers Zoomed into virtual meetings, 72% of Black workers and 65% of Latino workers remained trapped in front-line jobs with Covid mortality rates 2.1 times higher than those of their white counterparts.
The $5 trillion stimulus package that saved Wall Street failed to protect a variety of immigrant front-line workers (meatpackers, drivers, grocery store clerks) without relief checks or sick leave — the very essential workforce we applauded nightly from our doorsteps.
Five years after the start of the pandemic, America's recovery remains fractured by policy choices and viral aftershocks. Unemployment rates have plummeted, but at least 3.6% of adults now battle long Covid— a medical limbo where 68% see no symptom relief after two years. The administration's reinstatement of 8,000 unvaccinated troops contrasts starkly with long Covid's $168 billion annual productivity drain.
The unanswered questions loom largest: Could viral remnants awaken dormant diseases? Will long Covid's $3.7 trillion care burden eclipse initial deaths? The changes the Trump administration is implementing will hamper our ability to answer these questions. The Trump administration's 2025 executive orders have defunded 13 key health agencies, reducing budgets for pandemic preparedness while eliminating 5,200 public health positions, including 10% of the Centers for Disease Control and Prevention's outbreak and public health leadership.
Where inadequate testing capacity once plagued communities, we now face active suppression: New Food and Drug Administration guidelines have halted emergency use authorization for Covid rapid tests, privileging 'natural immunity' narratives over diagnostic transparency.
The supply chain vulnerabilities exposed in 2020 have become policy choices: The Department of Health and Human Services' travel restrictions now prevent epidemiologists from investigating H5N1 outbreaks unless mortality rates exceed 5%. As the MAHA Commission focuses on food additives and 'technological habit' reforms, the pandemic playbook that guided us through successive Covid waves gathers dust in agency archives. The lesson rings clear: America's public health vulnerabilities aren't merely systemic; increasingly, they're by design.
Five years after the start of the pandemic, America stands fractured yet paradoxically transformed. The crisis magnified our deepest divides — urban versus rural, privilege versus poverty, individualism versus collective survival — while stress-testing democracy itself. Yet from this crucible emerged unexpected resilience: telehealth revolutions, remote work permanence and newfound reverence for grocery clerks and nurses.
Now comes the existential task: weaving these fractured realities into a national tapestry that honors both our losses and our adaptations. The pressing question isn't whether we'll face another pandemic, but whether we can reconstruct a society in which Lorena's oxygen tubing and Wall Street's recovery packages occupy the same moral universe.
The answer to this question will determine whether we can confront the H5N1 outbreaks now spreading through Midwest dairy farms, reverse plummeting childhood vaccination rates' fueling measles resurgences in 32 states and address climate-driven disease vectors creeping northward — all while navigating a political landscape in which pandemic-era fractures have metastasized into active hostility toward public health institutions.
Our capacity to rebuild trust in science and bridge these divides may prove the ultimate test of whether Lorena's story becomes a relic of 2020s failures or a harbinger of a 2030s collapse.
This article was originally published on MSNBC.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca, Daiichi announce results from three trials on DATROWAY
AstraZeneca, Daiichi announce results from three trials on DATROWAY

Business Insider

time3 hours ago

  • Business Insider

AstraZeneca, Daiichi announce results from three trials on DATROWAY

Results from three trials continue to demonstrate the potential of DATROWAY in combination with various immunotherapies to improve outcomes in patients with non-small cell lung cancer, NSCLC, across multiple stages of the disease. These results from TROPION-Lung02, TROPION-Lung04 and NeoCOAST-2 were presented at the 2025 American Society of Clinical Oncology Annual Meeting. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate, ADC, discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (AZN). In 42 patients receiving first-line doublet DATROWAY plus pembrolizumab, an objective response rate of 54.8% was observed. In 54 patients receiving first-line triplet DATROWAY plus pembrolizumab and platinum chemotherapy, an ORR of 55.6% was observed. This analysis included patients enrolled during the dose escalation phase of the trial, where 4.8% and 40.7% of patients treated with the doublet and triplet regimens, respectively, received DATROWAY at a dose of 4 mg/kg versus 6 mg/kg. First results from cohort 5 of the TROPION-Lung04 phase 1b trial, presented during a poster session on Saturday, May 31, showed DATROWAY plus AstraZeneca's PD-1/TIGIT bispecific antibody rilvegostomig as a first-line treatment demonstrated an ORR of 57.5%, including one complete response and 22 partial responses in 40 patients with advanced or metastatic NSCLC. A disease control rate of 95% was seen. Final results from Arm 4 of the NeoCOAST-2 phase 2 platform trial evaluating neoadjuvant DATROWAY plus AstraZeneca's anti-PD-L1 therapy IMFINZI and single-agent platinum chemotherapy were presented during a poster session on Saturday, May 31 and showed the combination demonstrated a pathologic complete response rate of 35.2%

Arvinas, Pfizer announce VERITAC-2 trial did not reach statistical significance
Arvinas, Pfizer announce VERITAC-2 trial did not reach statistical significance

Business Insider

time3 hours ago

  • Business Insider

Arvinas, Pfizer announce VERITAC-2 trial did not reach statistical significance

Arvinas (ARVN) and Pfizer (PFE) announced detailed results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer, MBC, whose disease progressed following prior treatment with cyclin-dependent kinase, CDK, 4/6 inhibitors and endocrine therapy. These data, which were highlighted in the American Society of Clinical Oncology press briefing and selected for Best of ASCO, will be presented today in a late-breaking oral presentation and have been simultaneously published in the New England Journal of Medicine. In the trial, vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, PFS, among patients with an estrogen receptor 1, ESR1, mutation, reducing the risk of disease progression or death by 43% compared to fulvestrant. The median PFS, as assessed by blinded independent central review, BICR, was 5.0 months with vepdegestrant versus 2.1 months with fulvestrant. Investigator-assessed PFS was consistent with the BICR-assessed PFS. In patients with ESR1 mutations, vepdegestrant demonstrated a consistent PFS benefit over fulvestrant across all pre-specified subgroups. The trial did not reach statistical significance in improvement in PFS in the intent-to-treat population, with a median PFS of 3.7 months for vepdegestrant versus 3.6 for fulvestrant.

FDA approves Moderna's new lower-dose Covid-19 vaccine
FDA approves Moderna's new lower-dose Covid-19 vaccine

CNBC

time4 hours ago

  • CNBC

FDA approves Moderna's new lower-dose Covid-19 vaccine

The U.S. approved a new Covid-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option. The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose — a fifth of the dose of its current Covid-19 vaccine, Spikevax — by refining its immune target. The approval "adds an important new tool to help protect people at high risk of severe disease from Covid-19," Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus. That's the same limit that the FDA set in licensing another Covid-19 vaccine option from competitor Novavax. Those restrictions are a departure from how the U.S. has handled Covid-19 vaccines until now, reflecting skepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials. Moderna's existing vaccine doesn't face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall. The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective — and more by some measures — than the original shot, the company said. The news came just days after the Trump administration canceled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store